Differences in Outcomes Between Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer Patients in Upper Middle-Income versus High-Income Countries: A Retrospective Study from 4 Oncology Centers

CONCLUSIONS Results of our study showed superior survival among patients who were treated with dual first-line HER2 therapy as well as second-line trastuzumab emtansine therapy than in those patients in other centers where these drugs were not available. Raising awareness about this could help improve the situation.PMID:37264567 | DOI:10.12659/MSM.940356

Source: Medical Science Monitor - June 2, 2023 Category: Research Authors: Dragana Mileti ć Marija Kraljevi ć Emir Sokolovi ć Majana So če Marijana Milovi ć-Kovačević Simonida Bobi ć Timur Ceri ć Stjepko Ple ština Semir Be šlija Inga Marijanovi ć Source Type: research